Mapi Pharma: Glatiramer Acetate Depot: A Potential Long Acting Injection Solution for Multiple Sclerosis Patients
About The Event
Join us for a KOL Event with Mapi Pharma, where neurologists Aaron Miller, MD (Mount Sinai) and Carlo Tornatore, MD (Georgetown University Medical Center) will discuss Mapi Pharma’s Phase 3 Glatiramer Acetate (GA) Depot clinical results and the contribution a monthly GA Depot could have on the treatment of multiple sclerosis (MS) patients.
Mapi Pharma’s Principal Investigator, experts and CEO will discuss the Phase 3 GA Depot study results and provide a company update. Additionally, the KOLs will provide a comprehensive overview on the treatment landscape for Relapsing Forms of MS (RMS) and the unmet medical need for a long-acting monthly injection as compared to the approved daily or 3x/week GA injection,commercially available as Copaxone®, and its generic versions.
A live Q&A session will follow the formal presentations.